Weiting Liao
University of Hawaiʻi at Mānoa
ORCID: 0000-0003-0667-2046Also affiliated with University of Hawaii System, Sichuan University, Cancer Center of Hawaii, Sichuan Cancer Hospital, University of Hawaii Cancer Center
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma”.
Huiqiong Xu, David Hutton, Qiuji Wu, Yang Yang, Mingyang Feng +5 more
Yi Zhou, Weiting Liao, Eleonora Cossu, Matthias Evert, Shu Zhang +19 more
Diego F. Calvisi, Xin Chen, Weiting Liao
Weiting Liao, Giovanni Deiana, Davide Rizzo, Xin Chen, Diego F. Calvisi +1 more
Yi Zhou, Shu Zhang, Christine Farrar, Xuemei Xie, Jian Li +18 more